SADDLE BROOK, N.J., Dec. 15, 2009 (GLOBE NEWSWIRE) -- Herborium Group, Inc. (Pink Sheets:HBRM) www.herborium.com, a botanical therapeutics(R) company, is focusing its marketing efforts on the US $3.3 billion over the counter medicated skin care market.
Herborium develops licenses and markets proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company's flagship dermatological product is AcnEase(R), a proprietary, all herbal, systemic acne therapeutic, which has been validated through clinical testing. The results demonstrated that in adolescent acne approximately 95% of the patients responded positively to AcnEase while in individuals above 31 years of age the level of effectiveness was 80%. An overall positive response rate to AcnEase was 91%. Also for over 5 years Herborium has been marketing AcnEase it has registered 95.5% in consumer satisfaction rate. (www.acnease.com). AcnEase is manufactured in the USA in the GMP compliant facility.
"Given the recent notification by Hoffmann-La Roche Inc. to the U.S. Food and Drug Administration (FDA) of its intent to immediately discontinue further manufacturing and distribution of Accutane(R) (isotretinoin), the leading treatment for severe acne, /http://accutane.poweradvocates.com/ has demonstrated, we believe, the critical need for a safe and effective alternative. AcnEase is a perfect product to address acne problems affecting close to 60 million individuals in the U.S.," said Dr, Agnes P. Olszewski, CEO and President of Herborium Group."
We believe that the safety and efficacy of AcnEase(R) represents an ideal alternative to Accutane and similar drugs, and Herborium will be intensifying its efforts to bring our product to American and global consumers, as well as healthcare professionals and cosmeceuticals market in the US and globally." The global market for acne treatment is over $50 billion and Herborium is committed to tap into this market by marketing a global brand with a strong local distribution networks continued Dr. Olszewski.
"As we plan to address needs of all consumers with acne problems including females and males, AcnEase represents an especially valuable proposition for adults with a long term adult acne problems that have not found other treatment options successful. Our business plan calls for Herborium upon securing the necessary funding, to generate over $7 million in revenues during next twelve months at the very attractive gross profit margin of margin, and to double these revenue to $14 million in 2011 while maintaining its very attractive profit margin," concludes Dr. Olszewski.
About Herborium Group, Inc.
Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the forms 10-Q.